Extended-release Buprenorphine for Opioid Use Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method to initiate treatment for individuals with Opioid Use Disorder (OUD) using extended-release buprenorphine, a medication that helps manage withdrawal symptoms. Researchers aim to understand the safety and pharmacokinetics of this treatment. Participants will receive varying doses and undergo close monitoring to assess their body's reactions. The trial seeks individuals who have frequently used illicit opioids in the past month and have a positive urine test for fentanyl. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but you cannot participate if you've taken certain medications like buprenorphine, methadone, or specific drugs affecting liver enzymes in the past 30 days.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that extended-release buprenorphine (XR-BUP) is generally safe for people with opioid use disorder. One study found it effective for patients with mild withdrawal symptoms. Another study confirmed its safety for adults.
Although limited safety information exists for teenagers, the treatment is approved for adults. Patients should not mix it with other medications or alcohol without consulting a doctor. Overall, evidence suggests that XR-BUP is a safe option for those considering this treatment.12345Why are researchers excited about this trial's treatments?
Extended-release Buprenorphine is unique because it offers a once-monthly injection option for treating opioid use disorder, unlike standard treatments such as daily oral Buprenorphine. This extended-release formulation can improve adherence by reducing the need for daily dosing, which can be a significant barrier for some patients. Researchers are excited about this treatment because it maintains steady medication levels in the body, potentially reducing cravings and withdrawal symptoms more consistently than daily treatments. With dose options of 16mg, 24mg, and 32mg, it caters to individual patient needs, offering flexibility in managing the disorder effectively.
What evidence suggests that extended-release buprenorphine might be an effective treatment for opioid use disorder?
Research shows that extended-release buprenorphine (XR-BUP) effectively treats opioid use disorder (OUD). Studies have found that XR-BUP reduces drug use and keeps people in treatment longer than other treatments. For instance, one study found fewer positive urine tests for opioids among XR-BUP users. Another study showed that participants remained in treatment for six months and that XR-BUP was generally safe. Additionally, only a small number of patients experienced withdrawal symptoms when switching to XR-BUP. These findings suggest XR-BUP is a promising option for managing OUD.16789
Are You a Good Fit for This Trial?
This trial is for English-speaking adults over 18 who have used illicit opioids on most days in the past month, tested positive for fentanyl, and are diagnosed with Opioid Use Disorder. It's not suitable for those who don't meet these specific conditions.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Inpatient Admission
Participants are admitted to an inpatient unit for 3 days to receive fentanyl and XR-BUP
Treatment
Participants receive a single injection of XR-BUP and are monitored for withdrawal symptoms
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Extended-release Buprenorphine
Trial Overview
The study tests a new way to use extended-release Buprenorphine (XR-BUP) as a low-dose treatment to help people with opioid addiction. Participants will stay inpatient for three days, receive fentanyl to manage withdrawal symptoms, followed by XR-BUP injection.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
After the 20 participants have been completed, the next 10 participants will receive 32mg in a single-blind fashion.
After first 10 participants have been completed, the next 10 participants will receive 24mg in a single-blind fashion.
The first 10 participants will receive XR-BUP 16mg in single-blind fashion.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
University of Utah
Collaborator
Citations
Feasibility and effectiveness of extended-release ...
Compared to other MOUD, XR-BUP significantly reduced drug use, resulted in similar or higher treatment retention rates, fewer re-incarcerations, ...
Rapid vs Standard Induction to Injectable Extended ...
This randomized clinical trial compares the safety and effectiveness of rapid induction and standard induction onto extended-release ...
Extended-release injectable buprenorphine for the ...
The primary outcome was 6-month retention in XR-BUP treatment. Secondary outcomes included use of illicit opioids and safety. Results. Participants were mostly ...
Transition to Extended-release Buprenorphine Injectable ...
For Bup-XR-S studies, 75 patients transitioned to Bup-XR-S within 24 hours. Of patients, 4% experienced withdrawal symptoms requiring additional ...
Extended-release Buprenorphine Compared to Sublingual ...
The measure for the main comparative effectiveness outcome is number of urine drug screen (UDS) results negative for opioids at scheduled assessments during ...
Extended-Release 7-Day Injectable Buprenorphine for ...
7-day extended-release buprenorphine may be feasible in patients with opioid use disorder presenting with minimal to mild Clinical Opiate Withdrawal Scale ...
A Single-Dose Study to Evaluate the Relative ...
Serial blood samples were taken to measure buprenorphine plasma concentrations over 28 days and assess buprenorphine relative bioavailability.
What is Buprenorphine? Side Effects, Treatment & Use
Buprenorphine Safety Precautions · Do not take other medications without first consulting your doctor. · Do not use illegal drugs, drink alcohol, ...
9.
innovationdistrict.childrensnational.org
innovationdistrict.childrensnational.org/extended-release-buprenorphine-for-treatment-of-adolescent-opioid-use-disorder/Extended-release buprenorphine for treatment of adolescent ...
Extended-release buprenorphine has been shown to be a safe and effective medication in adults but not offered to adolescents due to lack of safety data.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.